James D. Anderson

Array ( [id] => 17312694 [patent_doc_number] => 20210401742 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-12-30 [patent_title] => Methotrexate Composition [patent_app_type] => utility [patent_app_number] => 17/470131 [patent_app_country] => US [patent_app_date] => 2021-09-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 4319 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 36 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17470131 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18619091 [patent_doc_number] => 11752113 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-09-12 [patent_title] => Polyamine transport inhibitors as antivirals [patent_app_type] => utility [patent_app_number] => 17/469827 [patent_app_country] => US [patent_app_date] => 2021-09-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 7 [patent_no_of_words] => 4871 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 103 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17469827 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17426741 [patent_doc_number] => 20220054449 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-02-24 [patent_title] => Combination Of Local And Systemic Therapies For Enhanced Treatment of Dermatologic Conditions [patent_app_type] => utility [patent_app_number] => 17/466600 [patent_app_country] => US [patent_app_date] => 2021-09-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8079 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 47 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17466600 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17334551 [patent_doc_number] => 20220000882 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-01-06 [patent_title] => METHOD OF TREATING DEMENTIA [patent_app_type] => utility [patent_app_number] => 17/459868 [patent_app_country] => US [patent_app_date] => 2021-08-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 4691 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 37 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17459868 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18254462 [patent_doc_number] => 20230081501 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-03-16 [patent_title] => RAPIDLY ACCELERATING FIBROSARCOMA PROTEIN DEGRADING COMPOUNDS AND ASSOCIATED METHODS OF USE [patent_app_type] => utility [patent_app_number] => 17/459179 [patent_app_country] => US [patent_app_date] => 2021-08-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 98199 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -29 [patent_words_short_claim] => 14 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17459179 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17441766 [patent_doc_number] => 20220062271 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-03-03 [patent_title] => LOTEPREDNOL AND MOXIFLOXACIN COMPOSITIONS AND METHODS [patent_app_type] => utility [patent_app_number] => 17/458532 [patent_app_country] => US [patent_app_date] => 2021-08-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 69950 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -29 [patent_words_short_claim] => 92 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17458532 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17441796 [patent_doc_number] => 20220062301 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-03-03 [patent_title] => BROMFENAC, PREDNISOLONE, AND MOXIFLOXACIN COMPOSITIONS AND METHODS [patent_app_type] => utility [patent_app_number] => 17/458289 [patent_app_country] => US [patent_app_date] => 2021-08-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 70367 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -29 [patent_words_short_claim] => 109 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17458289 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18122802 [patent_doc_number] => 20230008410 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-01-12 [patent_title] => LIQUID NALOXONE SPRAY [patent_app_type] => utility [patent_app_number] => 17/411507 [patent_app_country] => US [patent_app_date] => 2021-08-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19171 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 43 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17411507 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17718967 [patent_doc_number] => 20220211686 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-07-07 [patent_title] => FORMULATIONS OF 2-(4-CHLOROPHENYL)-N-((2-(2,6-DIOXOPIPERIDIN-3-YL)-1-OXOISOINDOLIN-5-YL)METHYL)-2,2-DIFLUOROACETAMIDE [patent_app_type] => utility [patent_app_number] => 17/412187 [patent_app_country] => US [patent_app_date] => 2021-08-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 35313 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -22 [patent_words_short_claim] => 40 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17412187 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18707467 [patent_doc_number] => 20230330041 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-10-19 [patent_title] => APPLICATION OF TRIS (HYDROXYMETHYL) AMINOMETHANE PHARMACEUTICALLY ACCEPTABLE SALT TO DRUGS FOR TREATING HYPERURICEMIA [patent_app_type] => utility [patent_app_number] => 18/043068 [patent_app_country] => US [patent_app_date] => 2021-08-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12233 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18043068 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18707467 [patent_doc_number] => 20230330041 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-10-19 [patent_title] => APPLICATION OF TRIS (HYDROXYMETHYL) AMINOMETHANE PHARMACEUTICALLY ACCEPTABLE SALT TO DRUGS FOR TREATING HYPERURICEMIA [patent_app_type] => utility [patent_app_number] => 18/043068 [patent_app_country] => US [patent_app_date] => 2021-08-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12233 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18043068 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18852672 [patent_doc_number] => 11850224 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-12-26 [patent_title] => Storage stable aqueous injectable solution comprising diclofenac [patent_app_type] => utility [patent_app_number] => 17/405292 [patent_app_country] => US [patent_app_date] => 2021-08-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 4318 [patent_no_of_claims] => 2 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 74 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17405292 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17412688 [patent_doc_number] => 20220047592 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-02-17 [patent_title] => METHODS OF TREATING RESPIRATORY DISEASES USING C5a INHIBITORS [patent_app_type] => utility [patent_app_number] => 17/400257 [patent_app_country] => US [patent_app_date] => 2021-08-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7879 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 25 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17400257 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17441711 [patent_doc_number] => 20220062216 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-03-03 [patent_title] => COMPOSITIONS AND METHODS FOR INCREASING LEAN-TO-FAT MASS RATIO [patent_app_type] => utility [patent_app_number] => 17/394649 [patent_app_country] => US [patent_app_date] => 2021-08-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14168 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 30 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17394649 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18902649 [patent_doc_number] => 20240018134 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-01-18 [patent_title] => 6-Substituted Pyridazine Compounds as SMARCA2 and/or SMARCA4 Degraders [patent_app_type] => utility [patent_app_number] => 18/019721 [patent_app_country] => US [patent_app_date] => 2021-08-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 34317 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -25 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18019721 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17828380 [patent_doc_number] => 20220265684 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-08-25 [patent_title] => COMPOSITIONS AND METHODS FOR TREATING ULCERATIVE COLITIS [patent_app_type] => utility [patent_app_number] => 17/392483 [patent_app_country] => US [patent_app_date] => 2021-08-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 2661 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17392483 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18389779 [patent_doc_number] => 20230157997 [patent_country] => US [patent_kind] => A9 [patent_issue_date] => 2023-05-25 [patent_title] => COMPOSITIONS COMPRISING A SEROTONERGIC TRYPTAMINE COMPOUND [patent_app_type] => utility [patent_app_number] => 17/388257 [patent_app_country] => US [patent_app_date] => 2021-07-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 28974 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -22 [patent_words_short_claim] => 46 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17388257 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18389779 [patent_doc_number] => 20230157997 [patent_country] => US [patent_kind] => A9 [patent_issue_date] => 2023-05-25 [patent_title] => COMPOSITIONS COMPRISING A SEROTONERGIC TRYPTAMINE COMPOUND [patent_app_type] => utility [patent_app_number] => 17/388257 [patent_app_country] => US [patent_app_date] => 2021-07-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 28974 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -22 [patent_words_short_claim] => 46 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17388257 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18994684 [patent_doc_number] => 11911502 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2024-02-27 [patent_title] => Pharmaceutical compositions and methods of using the same [patent_app_type] => utility [patent_app_number] => 17/388703 [patent_app_country] => US [patent_app_date] => 2021-07-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 34 [patent_figures_cnt] => 48 [patent_no_of_words] => 61248 [patent_no_of_claims] => 5 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 162 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17388703 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17227059 [patent_doc_number] => 20210353615 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-11-18 [patent_title] => COMPOSITIONS AND METHODS COMPRISING A COMBINATION OF SEROTONERGIC DRUGS [patent_app_type] => utility [patent_app_number] => 17/388252 [patent_app_country] => US [patent_app_date] => 2021-07-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 22070 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 35 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17388252 [rel_patent_id] =>[rel_patent_doc_number] =>)